<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Soluble human leukocyte antigen-G (sHLA-G) has been reported in <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and is implicated in mediating immune surveillance of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of our study is to detect serum sHLA-G levels in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and to determine whether sHLA-G may be helpful in distinguishing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> from benign colorectal diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Serum sHLA-G levels were determined using enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="3" pm="."><plain>Receiver operating characteristic (ROC) curve was used to evaluate the feasibility of sHLA-G in differentiating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> from benign colorectal diseases </plain></SENT>
<SENT sid="4" pm="."><plain>Median sHLA-G concentrations were significantly higher in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> colorectum, <z:mpath ids='MPATH_140'>hyperplastic polyp</z:mpath>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> and <z:mpath ids='MPATH_270'>adenoma</z:mpath> (<z:hpo ids='HP_0000001'>all</z:hpo> at p &lt; 0.001, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>ROC curve for sHLA-G revealed an area under the curve of 84.2%, and when 88.6 U/mL was used as cutoff, a sensitivity of 72.2% and a specificity of 87.8% were achieved </plain></SENT>
<SENT sid="6" pm="."><plain>Comparison of sHLA-G and carcinoembryogenic antigen ROC curves indicated that sHLA-G was superior to CEA in differentiating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> from benign colorectal diseases (p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>ROC curves analysis of the combined sHLA-G and CEA showed a higher detection capacity (area under the ROC curve, 87.4%) than that of markers considered singly </plain></SENT>
<SENT sid="8" pm="."><plain>These findings reveal that serum levels of sHLA-G are significantly increased in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> which may serve as a potent mediator of immune escape in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and sHLA-G may be a useful indicator in differentiating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> from benign colorectal diseases </plain></SENT>
</text></document>